1 / 27

Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis A Virus

Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis A Virus. Division of Viral Hepatitis. Hepatitis A Virus. Geographic Distribution of HAV Infection. Reported Cases of Hepatitis A, United States. 1995: Vaccine Licensed. 1996: ACIP recommendations. 1999 ACIP recommendations.

dwight
Download Presentation

Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis A Virus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Epidemiology and Prevention of Viral Hepatitis A to E:Hepatitis A Virus Division of Viral Hepatitis

  2. Hepatitis A Virus

  3. Geographic Distribution of HAV Infection

  4. Reported Cases of Hepatitis A, United States 1995: Vaccine Licensed 1996: ACIP recommendations 1999 ACIP recommendations Source: NNDSS, CDC

  5. States with Hepatitis A Rates > 10/100,000 1987-97 Rate > 20/100,000 Rate 10-20/100,000 Rate < 10/100,000

  6. Number of years that Reported Incidence of Hepatitis A Exceeded 10 Cases per 100,000, by County, 1987-1997

  7. Rate per 100,000 > = 20 10 - 19 5 - 9 0 - 4 Hepatitis A Incidence, United States 1987-97 average incidence 2002 incidence

  8. Avg. rate Rate Arizona 48 D.C. 14 Alaska 45 Georgia 12 Oregon 40 Arizona 8 New Mexico 40 Rhode Island 7 Utah 33 Connecticut 7 Washington 30 Kansas 7 Oklahoma 24 Maryland 6 South Dakota 24 Massachusetts 6 Idaho 21 Texas 6 Nevada 21 Florida 5 California 20 California 5 Top 10 States With the Highest Hepatitis A Rates NOW 2001 THEN 1987-1997

  9. Basics of Hepatitis A • RNA Picornavirus • Single serotype worldwide • Acute disease and asymptomatic infection • No chronic infection • Protective antibodies develop in response to infection - confers lifelong immunity

  10. Incubation period: • Jaundice by age group: • < 6 yrs • 6 – 14 yrs • > 14 yrs • Rare Complications: • Chronic sequelae: Average 30 days Range 15-50 days <10%40%-50% 70%-80% Fulminant hepatitis Cholestatic hepatitis Relapsing hepatitis None Hepatitis A – Clinical Features

  11. Acute Hepatitis A Case Definition For Surveillance • Clinical criteria of an acute illness with: • discrete onset of symptoms (e.g. fatigue, abdominal pain, loss of appetite, intermittent nausea, vomiting), and • jaundice or elevated serum aminotransferase levels • Laboratory criteria • IgM antibody to hepatitis A virus (anti-HAV) positive • Case Classification • Confirmed. A case that meets the clinical case definition and is laboratory confirmed or a case that meets the clinical case definition and occurs in a person who has an epidemiologic link with a person who has laboratory-confirmed hepatitis A during the 15-50 days before the onset of symptoms.

  12. Clinical illness Infection ALT IgM IgG Viremia Response HAV in stool 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Week Events In Hepatitis A Virus Infection

  13. Concentration of Hepatitis A Virus in Various Body Fluids Feces Serum Body Fluids Saliva Urine 102 104 100 106 108 1010 Infectious Doses per mL Source: Viral Hepatitis and Liver Disease 1984;9-22 J Infect Dis 1989;160:887-890

  14. Hepatitis A Virus Transmission • Fecal-oral • Close personal contact(e.g., household contact, sex contact, child day care centers) • Contaminated food, water(e.g., infected food handlers) • Blood exposure (rare)(e.g., injecting drug use, transfusion)

  15. Travelers; outbreaks uncommon Global Patterns of Hepatitis A Virus Transmission Disease Rate Peak Age of Infection Transmission Patterns Endemicity Low to high High Early childhood Person to person; outbreaks uncommon High Late childhood/ young adults Moderate Person to person; food and waterborne outbreaks Low Low Young adults Person to person; food and waterborne outbreaks Very low Very low Adults

  16. Risk Factors Associated with Reported Hepatitis A, 1990-2000, United States Source: NNDSS/VHSP

  17. Prevention of Hepatitis A • Vaccination (pre-exposure) • Immune globulin • Good hygiene • Clean water systems; avoidance of food contamination

  18. Hepatitis A Vaccination Strategy: Epidemiologic Considerations • Many cases occur in community-wide outbreaks • no risk factor identified for 40-50% of cases • highest attack rates in 5-14 year olds • children serve as reservoir of infection • Groups at increased risk of infection • travelers to developing countries • men who have sex with men • illegal drug users • persons with chronic liver disease

  19. Hepatitis A Prevention – Immune Globulin • Pre-exposure • travelers to intermediate and high HAV-endemic regions • Post-exposure (within 14 days) Routine • household and other intimate contacts Selected situations • institutions (e.g., day care centers) • common source exposure (e.g., food prepared by infected food handler)

  20. ACIP Recommendations – Hepatitis A Vaccine Pre-exposure Vaccination • Persons at increased risk for infection • travelers to intermediate and high HAV-endemic countries • MSM (Men who have sex with men) • illegal drug users • Persons who have clotting factor disorders • persons with chronic liver disease • Communities with historically high rates of hepatitis A -routine childhood vaccination

  21. Duration of Protection after Hepatitis A Vaccination • Persistence of antibody • At least 5-8 years among adults and children • Efficacy • No cases in vaccinated children at 5-6 years of follow-up • Mathematical models of antibody decline suggest protective antibody levels persist for at least 20 years • Other mechanisms, such as cellular memory, may contribute

  22. Hepatitis A VaccineImmunogenicity, Side Effects • Immunogenicity in children, adolescents, adults: • 94-100% positive 1 month after dose 1 • 99-100% positive after dose 2 • Most common side effects: • Sore injection site (50%), headache (15%), malaise (7%) • No severe reactions known • Safety in pregnancy unknown (risk likely is low) Currently licensed for aged 1 year and older

  23. Use of Hepatitis A Vaccine for Infants • Hepatitis A vaccine is licensed only for persons aged 1 year and older • Safe and immunogenic for infants without maternal antibody • Presence of passively-acquired maternal antibody blunts immune response • all respond, but with lower final antibody concentrations • Age by which maternal antibody disappears is unclear • still present in some infants at one year • probably gone in vast majority by 15 months

  24. ACIP Recommendations, 1999 Implementation • Children Who Should be Routinely Vaccinated • living in states, counties, and communities where the average hepatitis A rate was  20 cases/100,000 during baseline period. • Children Who Should be Considered for Routine Vaccination • living in states, counties, and communities where the average hepatitis A rate was <20 but  10 cases/100,000 during the baseline period.

  25. ACIP Recommendations – Hepatitis A Vaccine Post-vaccination Testing • Not recommended because of the high response rate among vaccinees (95% after dose one, 100% after two) • No commercially available test to measure vaccine response

  26. Hepatitis A in the United States-2002 • National rate lowest yet recorded • Continued monitoring needed to determine if low rates sustained and due to vaccination • Evaluation of age-specific rates to assess impact of vaccination strategy • Rates increasing in some states • Occurring among adults in high risk groups (e.g. MSM, drug users)

  27. Long-term Hepatitis A Prevention Strategy • Sustain ongoing vaccination • Lower disease incidence • Catch-up vaccination of children and adolescents • Further reduce incidence • Vaccination of high-risk adults • Routine vaccination of all children nationwide

More Related